{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-180722","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.121349+00:00","generated_at":"2026-06-13T13:13:40.378251+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX raises $30M via private placement of units with warrants","bullets":["Gross proceeds of $30M from unit sale at $2.08 each; closing expected July 3, 2023.","Each unit: 1 share or Pre-Funded Warrant ($0.00001 exercise, 20-yr term) plus Tranche 1 ($4.16, exp. 2025) and Tranche 2 ($6.24, exp. 2026) warrants.","No underwriter; resale registration statement to be filed within 60 days after closing.","Pre-funded and Tranche warrants may not be exercised if holder would exceed 9.99% ownership (adjustable to 19.99%).","Exercise price of Tranche warrants subject to reset if future offering below $4.16, but not below $2.08."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-180722","json":"https://secwatch.observer/filing/0001193125-23-180722.json","markdown":"https://secwatch.observer/filing/0001193125-23-180722.md","text":"https://secwatch.observer/filing/0001193125-23-180722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523180722/0001193125-23-180722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523180722/d500160d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:13:40.378251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e403cb4797e8cebadf568cdcae3449f0b9dd1107","claim":"CytomX Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $30.0 million (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, CytomX Therapeutics, Inc. (the “Company”) entered into a unit purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523180722/0001193125-23-180722-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $30.0 million"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}